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Abstract 
 
Drug addiction is a chronic disease which affects millions of people worldwide with critical 
social and economical impact, besides the health burden. Repetitive exposure to drugs of 
abuse induces long-lasting neuroadaptative changes that promote drug-seeking behaviors.  
The causes of vulnerability to addiction, although its complexity, have been pointed to be in 
association with environmental, social and/or genetic factors.  
Pharmacogenetics and more recently pharmacogenomics developments with technical 
genetic resources, such as candidate gene and genome-wide analysis approaches, have played 
an important role unraveling the possible responsible genetic variants, like SNP or VNTR 
that may influence the vulnerability or having a protective effect in chemical dependence.  
Since drug addiction is a complex disease spectrum, genetic results may be seen as 
contradictory in some studies, but some genetic variants have been proven to be 
consistently associated to disease. For example, 136A allele of ADH4 gene, coding for 
alcohol dehydrogenase, has been associated with increased susceptibility to alcohol 
dependency while the ADH1B*2 variant has shown to confer a protective effect for alcohol 
dependence. 
The use of Next Generation Sequencing (NGS) platforms allowing massively parallel 
sequencing for assessing entire genome in a few days will probably grow, with a widespread 
use for obtaining a huge amount of genetic information as a powerful tool for deeper 
understanding and for development of novel therapeutic approaches to drug addiction. 
 
Keywords: drug addiction, genetic variations, pharmacogenetics, pharmacogenomics. 
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Resumo 
 
A dependência de drogas é uma doença crónica que afecta milhões de pessoas em todo o 
mundo com impacto social e económico crítico, além do problema de saúde em si. A 
exposição repetida ao abuso de drogas induz alterações neuroadaptativas duradouras que 
promovem comportamentos de busca de drogas.  
As causas da vulnerabilidade para a dependência, apesar da sua complexidade, têm sido 
apontados para a associação com factores ambientais, sociais e / ou genéticas.  
A farmacogenética e, mais recentemente desenvolvimentos na farmacogenómica com 
recursos técnicos genéticos, como as abordagens de gene candidato e genome-wide analysis, 
têm desempenhado um papel importante para desvendar as possíveis variantes genéticas 
responsáveis, como SNP ou VNTR que podem influenciar a vulnerabilidade ou ter um efeito 
protector na dependência química. 
Como a dependência de drogas é uma doença complexa, os resultados genéticos podem ser 
considerados contraditória em alguns estudos, mas algumas variantes genéticas têm sido 
consistentemente associadas à doença. Por exemplo, o alelo 136A do gene ADH4, que 
codifica para a álcool-desidrogenase, tem sido associado com um aumento da 
susceptibilidade à dependência do álcool, enquanto a variante ADH1B * 2 demonstrou 
conferir um efeito protector para a dependência do álcool.  
O uso de sequenciamento de plataformas de próxima geração (NGS) permitindo 
sequenciamento paralelo em massa para avaliar o genoma inteiro em poucos dias, irá 
provavelmente crescer, com um uso generalizado para a obtenção de uma enorme 
quantidade de informação genética como uma ferramenta poderosa para a compreensão 
mais profunda e para o desenvolvimento de novas abordagens terapêuticas para dependência 
de drogas.  
 
Palavras-chave: dependência, drogas, variações genéticas, farmacogenética, farmacogenómica. 
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1. Introduction 
 
Drug addiction, also known as substance dependence, is a chronically relapsing disorder 
characterized by: (i) compulsion to seek and take a drug despite significant harmful 
consequences, (ii) loss of control in limiting intake and recurrent failure to control the 
behavior and (iii) emergence of a negative emotional state (e.g. dysphoria, anxiety, irritability) 
when access to the drug is prevented. According to DSM-5, craving has been added as a new 
criterion for the diagnosis of substance abuse. [1-4] 
 
2. Neurobiology of addiction 
In individuals who are vulnerable to addiction, repetitive exposure to the agent induces long-
lasting neuroadaptative changes that further promote drug-seeking behaviors and ultimately 
lead to persistent and uncontrolled patterns of use. These neuroadaptative changes are the 
bases for the tolerance, craving and withdrawal and lead to a motivational shift. [5] 
Family history studies indicate that biological relatives of an individual who has been 
diagnosed with psychoactive substance dependence, bulimia, pathological gambling, or sexual 
addiction are at significantly higher risk, compared to the general population, to develop, at 
some point in their lives, one of these disorders. [2] 
The reward pathway of the mammalian brain consists of synaptically interconnected 
neurons, which link the ventral tegmental area (VTA), nucleus accumbens (NAc), ventral 
pallidum (VP), and medial prefrontal cortex (MPFC). This circuit is strongly implicated in the 
neural processes underlying drug addiction, and its inhibition is implicated in such 
phenomena as withdrawal dysphoria and dysphoria-mediated drug craving. [6] 
Exposure and access to hedonic stimuli, such like addictive drugs, results in the pleasurable, 
positively reinforcing effects of the drug and also ‘desire’ for it when drug is not present. 
One of the most important brain areas for reinforcement and pleasure is the NAc in the 
forebrain region. It receives input from dopamine-producing cells in the midbrain called the 
ventral tegmental area (VTA). In fact, the VTA–NAc pathway seems to be a site where 
virtually all drugs of abuse converge to produce their acute reward signals. The VTA 
contains dopaminergic cells that project to the frontal cortex and limbic system. Release of 
dopamine into the frontal cortex and NAc results in the subjective experience of pleasure. 
[7 – 9] 
It is known that the ‘first-stage’ neurons originate from an unrelated group of ventral limbic 
forebrain loci termed the “anterior bed nuclei” of the medial forebrain bundle (MFB). These 
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‘first-stage’ neurons are myelinated and moderately fast-conducting, and they project 
posteriorly through the MFB to synapse on VTA dopaminergic cells. The ‘second-stage’ 
dopamine (DA) releasing neurons project anteriorly within the MFB to synapse in the NAc. 
From NAc, ‘third-stage’ enkephalinergic neurons carry the reward signal to VP. This ‘third-
stage’ pathway appears to be critical for the phenotype expression of reward-related and 
incentive- related behaviors. A portion of the ‘third-stage’ pathway consists of 
enkephalinergic NAc projection neurons which co-localize with γ-aminobutyric acid (GABA) 
as a co-transmitter. [6] 
The GABAergic and glutamatergic neural inputs into this core reward system have been 
recognized as critically important in the regulation of reward processes and reward-driven 
behaviors. [6] 
The acute rewarding properties of psychostimulant drugs have long been known to depend 
on activation of the mesolimbic DA system and dopaminergic neuronal projections have 
been identified as the central component of this brain reward system. They extend from the 
VTA of the midbrain to parts of the limbic system, especially to the NAc shell and the frontal 
cortex. Both natural stimuli and several, but not all, substances of abuse - most prominently 
cocaine, amphetamine, and opiates, are able to increase the release of DA in the NAc. The 
firing of dopaminergic neurons in the VTA is usually under the control of GABAergic γ -
amino-butyric acid interneurons. Dopamine is released when the reward is achieved in 
addition to the presence stimuli that predict recompense. [6, 7, 11] 
Addictive drugs activate the above-mentioned brain reward processes. Such drugs appear to 
activate the ‘second-stage’ DA neurons of the VTA/NAc axis, thus, producing the 
pleasurable/ euphoric effects. If a drug activates the VTA system and increases dopamine in 
the NAc, it will cause reinforcement and addiction. However, the mechanisms of this effect 
and the magnitude of increased dopamine levels in these areas are often different. For 
example, some drugs, such as the amphetamines, increase release of dopamine from 
presynaptic terminals in the NAc. Certain drugs, such as cocaine, block the reuptake of 
synaptic dopamine into the presynaptic neurons. Other drugs of abuse, such as alcohol, act 
on the cell bodies in the ventral tegmentum that produce DA. Addictive opiates, such as 
heroin and oxycodone, inhibit GABA cells that surround and normally suppress VTA cell 
dopaminergic activity. Not all drugs activate the dopaminergic system to the same extent 
and, therefore, they have different addictive potentials. [6, 8] 
Different types of drugs will elicit distinct responses. Cocaine and amphetamines activate the 
release of dopamine in the NAc and amygdala via direct actions on dopamine terminals. 
Pharmacogenomics of Drug Addiction 2014 
 
6 
 
Opioids activate opioid receptors in the VTA, NAc, and amygdala via direct actions on 
interneurons. Opioids facilitate the release of DA in NAc via an action either in the ventral 
tegmental area or the nucleus accumbens. But also it has been hypothesized that it may 
activate elements independent of the dopamine system. Alcohol activates GABAA receptors 
in the VTA, NAc, and amygdala via either direct action at the GABAA receptor or through 
indirect release of GABA. Alcohol facilitates the release of dopamine in the nucleus 
accumbens either in the ventral tegmental area or the nucleus accumbens. Nicotine activates 
nicotinic acetylcholine receptors in the ventral tegmental area, nucleus accumbens, and 
amygdala, either directly or indirectly, acting in the interneurons. [1] 
Identification of specific components of the basal forebrain that have been associated with 
drug reward have focused on the extended amygdala, which includes the central nucleus of 
the amygdala, the bed nucleus of the stria terminalis, and a transition zone in the medial 
(shell) part of the nucleus accumbens. The extended amygdala receives numerous afferents 
from limbic structures, such as the basolateral amygdala and hippocampus, and sends 
efferents to the medial part of the ventral pallidum and a large projection to the lateral 
hypothalamus, further defining the specific brain areas that interface classical limbic 
(emotional) structures with the extrapyramidal motor system. [1, 10] 
The structures comprising the extended amygdala may further define the neuronal 
substrates for the acute reinforcing actions of drugs of abuse. Amygdala appears to act in 
accord with the ventral striatum (VS) to pick up stimuli that are not just emotionally salient 
but highly relevant to a task-dependent reward. [1, 11]  
Neuroscience research has demonstrated a shared vulnerability in neuronal circuits that 
underlies the abuse of psychoactive substances toward delineating the neurobiological 
processes that constitute this vulnerability. Among those affected paths, we may detach 
dysregulation of mesolimbic DA circuits, reduction in DA D2 receptors (DRD2), 
abnormalities in the orbitofrontal cortex and the anterior cyngulate gyrus, anomalies in the 
ventromedial prefrontal cortex, differential genetic variants of cannabinoid receptor 1 
(CB1/Cnr1) affecting its function, up-regulation of brain-derived neurotrophic factor 
(BDNF). [6] 
The evidences gathered by the scientific researchers suggest that the recognizable behaviors 
that characterize the addiction phenotype (compulsive drug consumption, impaired self-
control, and behavioral inflexibility) represent unbalanced interactions between complex 
networks (that form functional circuits) implicated in goal-directed behaviors.[12]  
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The ability of certain behavioral routines to become deeply ingrained, after enough 
repetition, helps to explain both the difficulty of suppressing them (i.e. compulsion ) and the 
ease with which they bounce back after extinction (i.e. relapse). Habituation appears to be 
based mainly in the mesostriatocortical circuits that ‘re-code’ the behavioral outcome of 
repetitive actions in a process that was aptly referred to as the ‘chunking’ of action 
repertoires. [12] 
Drug-induced adaptations anywhere along this bidirectional circuitry, between VTA and the 
neighboring substantia nigra (SN), ventral and dorsal striatum, thalamus, amygdala, 
hippocampus, subthalamic nucleus, and the prefrontal cortex (PFC) can trigger or facilitate 
the addictive process by disrupting reward-based learning via the modulation of regional 
neuronal excitability. [12] 
Many studies have established that DA signals emanating from the VTA/SN and arriving in 
the striatum, play a pivotal role in learning from past experience and orchestrating 
appropriate behavioral responses. Whether directly or indirectly, all addictive drugs have the 
power to cause large and transient increases in DA from VTA neurons that project primarily 
into the NAc of the ventral striatum (VS), but also to the dorsal striatum, amygdala, 
hippocampus and PFC. [12] 
At the cellular and molecular level, genetic vulnerability to addictive drugs correlates, for 
example, with decreased neurofilamentary transport for tyrosine hydroxylase (the rate-
limiting intraneuronal DA synthetic enzyme) in VTA/NAc DA reward-related neurons. This 
produces a DA deficiency in these VTA/NAc brain reward neurons, which is hypothesized 
to underlie vulnerability to addictive drug action. [6] 
Another type of DA dysfunction in the VTA/NAc brain reward axis centers on a deficiency 
affecting DRD2 receptors. Blum and colleagues have long hypothesized that a deficit in 
normal DRD2 function in mesoaccumbens brain reward loci may confer vulnerability to drug 
addiction. [6] 
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3. Epidemiology and Etiology of Dependence 
3.1 Epidemiological Facts 
 
The costs of drug abuse and drug addiction to society are enormous in terms of both direct 
and indirect expenses associated with secondary medical events, social problems, and loss of 
productivity. In the United States alone, it is estimated that expenditure of illicit drug abuse 
and addiction is around $161 billion (Office of National Drug Control Policy, 2001). It is 
estimated that alcoholism costs to the society about $180 billion per year, and tobacco 
addiction require $155 billion (Centers for Disease Control and Prevention, 2004). In 
France, the total cost of drug use is $41 billion, including $22 billion for alcohol, $16 billion 
for tobacco, and nearly $3 billion for illicit drugs. [13] 
Almost a quarter of the adult population in the European Union, corresponding to over 80 
million adults, are estimated to have used illicit drugs at some point in their lives. Cannabis 
was the most popular (73.6 million users), with lower estimation reported for the lifetime 
use of cocaine (14.1 million users) (Figure 1). Levels of lifetime use vary considerably 
between countries, from around one-third of adults in Denmark, France and the United 
Kingdom, to less than 1:10 in Bulgaria, Greece, Cyprus, Hungary and Portugal. [13] 
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Figure 1: Lifetime prevalence of drug by European Union Countries (data available from 
http://www.emcdda.europa.eu/stats13, 2014) 
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Europe faces the dual challenge of developing effective responses to emerging problems and 
continuing to address the needs of drug users in long-term treatment. [13] 
The bulk of costs related to treating drug use continue to stem from problems that are 
rooted in the heroin ‘epidemics’ of the 1980s and 1990s. Although initiation into heroin use 
may be in decline, heroin dependence, characterized by a chronic disease model with cycles 
of relapse and treatment entry, remains a key focus for interventions. The European Union 
has invested considerably high amounts of money in providing treatment opportunities for 
this group, currently with an estimation of three-quarters of a million in opioid substitution 
treatment. [13] 
 
3.1.1- Opioid: Data of Consumption and Treatment 
The illicit use of opioids remains responsible for a disproportionately large share of the 
morbidity and mortality resulting from drug use in Europe. The opioid most used in Europe 
is heroin, which may be smoked, snorted or injected. A range of other synthetic opioids, 
such as buprenorphine, methadone and fentanyl, are also available on the illicit market. 
Opioid use tends to be highest among marginalised populations in urban areas. [13] 
The average annual prevalence of problems due to opioid use among adults (15–64) is 
estimated to be around 0.4 %, the equivalent of 1.3 million users in Europe in 2012 (Table 1). 
[13] 
 
 
Table 1: Opioids estimate uses in European Union [13] 
1.3 million users (15–64 years of age) 
3.5% of all deaths of Europeans with 15–39 years old are due to drug overdoses, 
opioids are found in about three-quarters of fatal overdoses 
Principal drug in about 45% of all drug treatment requests in the European Union 
700,000 opioid users received substitution treatment in 2012 
 
Addicted individuals using opioids, mainly heroin, as their primary drug, represent 46% of all 
drug users who entered specialized treatment during 2012, in Europe (180,000 subjects), and 
around 26% of those initiated treatment for the first time. [13] 
In Figure 2, it is presented the data of drug users who entered treatment for the first time in 
2011. 
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Figure 2: New addicted patients (%) entering treatment by primary drug heroin, cocaine, 
cannabis, other stimulants and other drugs during 2011 in Europe (data available from 
http://www.emcdda.europa.eu/stats13, 2014). 
 
In 2012, in the majority of European countries, more than 10 % of first-time opioid users 
entering specialised treatment were misusing opioids other than heroin (Figure 3). These 
included methadone, buprenorphine and fentanyl. In some countries, these drugs now 
represent the most common form of opioid abusing use. [13] 
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Figure 3: First-time entrants in treatment due to abuse of opioids other than heroin: trends 
in as percentage of all first-time entrants with opioids as primary drug. (data available from 
European Monitoring Centre for Drugs and Drug Addiction- European Drug Report 2014: 
Trends and developments. Luxembourg: Publications Office of the European Union, 2014) 
 
While deaths related to heroin are generally falling, deaths related to synthetic opioids are 
increasing, and in some countries now exceed those attributed to heroin. Substitution 
treatment, typically combined with psychosocial interventions, is the most common 
treatment for opioids’ dependence in Europe. The evidences available support this combined 
approach for keeping patients in treatment, as well as for reducing illicit opioid use, drug-
related harms and mortality. [13] 
 
3.1.2- Cocaine: Data of Consumption and Treatment 
 
Cocaine powder is primarily sniffed or snorted, but is also sometimes injected, while crack 
cocaine is usually smoked. Among regular users, a broad distinction can be made between 
more socially integrated and moderate consumers, who may be using the drug in a 
recreational context, and more marginalised drug users, who use cocaine, often along with 
opioids, as part of a chronic drug problem. [13] 
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Cocaine is the most commonly used illicit stimulant drug in Europe (Table 1) but decreases 
in cocaine use are also observable in the most recent data. [13] 
 
 
Table2: Cocaine estimate users in European Union [13] 
14.1 million or 4.2 % of adults (15–64 years of age) used cocaine in their  lifetime 
3.1 million or 0.9 % of adults (15–64) used cocaine in the last year 
2.2 million or 1.7 % of young adults (15–34) used cocaine in the last year 
0.2 % and 3.6 % — lowest and highest national estimates of last year cocaine use 
among young adults  
 
 
In Figure 4 it is presented data of last 12 months prevalence of cocaine abuse in several 
European Union countries, among all adults, young adults and youth.  
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Figure 4: Last 12 months prevalence of cocaine use among all adults - aged 15–64, young 
adults - aged 15–34 and youth - aged 15–24 (data available from 
http://www.emcdda.europa.eu/stats13, 2014) 
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Cocaine was cited as the primary drug for 14% of all reported abusers entering specialised 
drug treatment in 2012 (55,000), and 18% of those entering treatment for the first time 
(26,000) (See Figure 2 for data of 2011). Differences exist between countries, with around 
90% of all cocaine clients being reported by only five countries (Germany, Spain, Italy, 
Netherlands, United Kingdom). [13]  
In 2012, around 77,000 cases of seizures due to cocaine were reported in the European 
Union, amounting to 71 tonnes of the drug being intercepted. The number of cocaine 
seizures reported in 2012 remains at a high level, compared to 2002. However, it has 
decreased from an estimated peak of around 95,000 seizures in 2008. [13] 
Decreases in the quantity of cocaine apprehended are most observable in the Iberian 
Peninsula, particularly in Portugal between 2006 and 2007, and more gradually in Spain 
between 2006 and 2011. [13] 
Survey data illustrate the geographical differences in stimulant use patterns in Europe. 
Cocaine is more prevalent in the south and west of Europe, amphetamines in central and 
northern countries, and ecstasy — albeit at low prevalence levels — in countries in the 
south and east, among young adults (Figure 2). [13] 
 
Figure 5: Predominant stimulant drug by last year prevalence among young adults(15–34 
years old) (data available from European Monitoring Centre for Drugs and Drug Addiction- 
European Drug Report 2014: Trends and developments. Luxembourg: Publications Office of 
the European Union, 2014). 
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3.2- Current Status in Portugal 
 
In the study conducted in 2012 in the general Portuguese Population (15-64 years of age), 
cannabis, ecstasy and cocaine were the illicit substances preferably used by the Portuguese 
with lifetime prevalence (at least one use experience) respectively of 9.4%, 1.3% and 1.2%. 
Between 2007 and 2012, in the set of the Portuguese population, it was verified for almost 
all drugs a decrease in lifetime prevalence (of any illicit drug from 12% to 9.5%) and recent 
use (of any illicit drug from 3.7% to 2.7%) as well as decrease in continuity rates of use (of 
any illicit drug from 31% to 28%). [14] 
In 2012 was held in Portugal the III National Population Survey on Psychoactive Substances 
in the Portuguese Population (INPP – Inquérito Nacional ao Consumo de Substâncias 
Psicoactivas na População Portuguesa). [14] 
In 2012, similarly to 2007 and 2001, cannabis was the illicit substance that registered the 
higher lifetime prevalence of use – at least one use experience in life – and recent use – in 
the last 12 months at the date of the enquiry, either in general population (15-64 years old) 
and in the young adult population (aged 15-34). These prevalences were, respectively, 9.4% 
and 2.7% in general population, and 14.4% and 5.1% in young adults. [14] 
Comparatively to other European countries, with studies carried out between 2010 and 
2012, and the same population age range (15-64 years) as reference, Portugal continues to 
present prevalence of use of illicit substances below the average values registered in those 
countries. [14] 
 
3.3- Etiological Causes of Dependence 
 
Environmental exposure, including social background and genetic factors contribute to 
individual differences in vulnerability to initiating use of addictive agents and in vulnerability 
to the shift from substance use to addiction. [15] 
The addictions encompass also non-substance related behaviors, such as sexual, internet, 
gambling or food addiction, that are widespread and that might access the same 
neurobiological pathways that modulate reward, impulsive and compulsive behavior and 
mood. [15] 
The origins of addiction vulnerability are complex and wide-ranging; the underlying genetic 
factors need to be identified to solve the puzzle of what causes the pervasive and relatively 
intractable disorders. [15] 
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Drugs differ in their addiction liability, which is the relative potential of an agent to lead to 
addiction. Cocaine and opiates, among the most addictive substances, are also among the 
most heritable, concerning family history. On the other hand, hallucinogens are among the 
least addictive, and are also the least heritable. These data seem to point towards an 
inheritance of variation in the core of neurobiological basis of addiction, such as the 
pathways that mediate reward, behavioral control, compulsivity, or stress and anxiety 
response. [15] 
Addictions are inherited as common, complex diseases that show no obvious pattern of 
Mendelian transmission, but with evident genetic involvement and heritability. The 
identification of specific genes and functional loci moderating vulnerability has been 
challenging because of the genetic complexity of addictive disorders, namely related with 
underlying neurobiological pathways. This complexity derives from multiple sources including 
incomplete penetrance, phenocopies, variable expressivity, gene-environment interactions, 
polygenicty, genetic heterogeneity, among others. [5] 
It is tempting to imagine that addictions are polygenic, with vulnerability arising from the 
simultaneous action of functional variations at multiple genes. However the complexity of 
neurocircuitry and neurobiology can lead to highly intricate genetic heterogeinity, meaning 
that a single genetic variation can determine vulnerability, but different variants can be 
enough for expression of the disease in different individuals and families. [15] 
One strategy to discover gene effects in etiologically complex diseases, such as addiction, is 
the deconstruction of phenotypes into elements that are etiologically less complex. 
Intermediate phenotypes access mediating mechanisms of genetic and environmental 
influences. These heritable intermediate phenotypes are endophenotypes. For example, 
alcohol-induced flushing is a protective alcohol-related endophenotype, influenced by alleles 
mediating variation in alcohol metabolism and low response to alcohol has been associated 
with genetic variation, namely in the serotonin transporter gene (SLC6A4) and in the gene 
encoding the subunit a6 of the γ-aminobutyric acid receptor A (GABRA6). [5] 
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4. Tools for Identification of Genetic Markers 
 
A first step must be given to evaluate the evidence concerning the extent to which substance 
abuse disorders may be influenced by heritable factors. [16] 
There are two main types of studies, linkage and association studies, conducted to establish 
whether genes and their variants may be involved in causing or in vulnerability to drug 
addiction. [16, 17] 
Linkage studies use families to provide evidence of how close a genetic marker is to an allele 
causing the phenotype under study, whereas association studies may be performed with 
unrelated individuals. Strong evidences can be derived from a range of family-based 
genetically informative research designs including family, adoption and twin studies. [16, 17] 
Early family-based studies provided initial clues of potential heritable influences by examining 
the risk of substance use addictive disorders in the first-degree relatives of individuals either 
with or without a substance use disorder. [16, 17] 
The classical twin study design makes use of data from monozygotic (MZ) and dizygotic (DZ) 
twin pairs, reared together, to attempt to disentangle the role of genetic and environmental 
influences on population variation in a measurable phenotype. Genetic variants are shared 
completely between members of MZ twin pairs while DZ pairs share on average 50% of 
their genetic variants. In any case this can only be a starting point, as a demonstration that 
there are heritable factors that influence individual differences in vulnerability to addiction. 
[16] 
Case control-association studies are another approach to identify variants involved in 
addictions. It consists of selecting genes that are likely to be involved in the physiological 
effect of the specific drug under consideration in a neurotransmitter system (receptors, 
transporter, metabolizing enzymes, etc), related to drug taking behaviors. Genetic variants 
are identified in these candidate genes. Cases and controls are genotyped for the variants 
and statistical analyses are then applied to evaluate the probability that a given variant allele 
is associated with the drug addiction. [17] 
In association studies, the ethnicity of the subjects must be carefully evaluated because some 
genes’ allelic frequencies vary widely among ethnic groups. If this issue is not addressed, 
there are bias that compromise interpretation of results. [17] 
The techniques for conducting association studies have seriously improved once thousands 
of variants can be included using gene array technology. To locate and identify genes and 
chromosomal regions that are associated with specific addictions, genome-wide scans can be 
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performed on affected and control subjects populations, in order to identify significant 
differences in frequency distribution, allowing to point candidates contribution for risk or 
vulnerability to addiction. [17] 
Candidate gene approaches have tended to focus upon specific sets of genes based on 
assumptions about the importance of certain genes in addiction, usually assessing a small 
number of genomic markers. These assumptions were based mainly in the mechanisms of 
action of particular drugs of abuse, e.g. dopamine systems (cocaine and other stimulants), 
opioid systems (heroin and other opiates), GABAergic systems (ethanol), among others. [16] 
Candidate gene and genome-wide analyses have been increasingly integrated in research, in 
order to identify genetic variations influencing addiction. [5] 
Genome-wide association studies measures and analyzes DNA sequence variations from 
across the human genome in an effort to identify multiple genetic risk factors for diseases 
that are common in the population under study. [19] 
A few concepts must be clarified before carrying on with the analysis of methodology to 
discover genetic variations. One of these concepts is the common disease/ common variant 
(CD/ CV) hypothesis. This hypothesis simply states that common disorders are likely 
influenced by genetic variation that is also common in the population. Another important 
concept is linkage disequilibrium (LD). LD is a property of SNPs on a contiguous stretch of 
genomic sequence that describes the degree to which one allele of a SNP is inherited or 
correlated with an allele of another SNP within a population. LD is a terms used to designate 
for the chance of co-inheritance of alleles at different loci. LD is due to recent migration, 
selection or recent mutation. The SNPs that are specifically selected to capture the variation 
at nearby sites in the genome are called tag SNPs, because alleles for these SNPs tag the 
surrounding stretch of LD. Patterns of LD are population specific and as such, tag SNPs 
selected for one population may not work well for other populations. [19, 20] 
Genome-wide association studies were made possible by the availability of chip-based 
microarray technology for assaying more than one million SNPs at once. Two primary 
platforms have been used for most commonly used GWAS. These include products from 
Illumina (San Diego, CA) and Affymetrix (Santa Clara, CA). The Affymetrix platform prints 
short DNA sequences as a spot on the chip that recognizes a specific SNP allele. Alleles are 
detected by differential hybridization of the target DNA sample. On the other, hand Illumina 
uses a bead-based techonology with slightly longer DNA sequences to detect alleles. [19] 
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As compared to candidate gene investigation, genome-wide association studies (GWAS) 
have the advantage of covering the entire genome in an hypothesis-free way and it is a 
powerful method to detect relatively common alleles of moderate effect. [5] 
Another advantage of GWAS is related to the fact that the same genotyping arrays are 
obtained in different samples facilitating the comparison of results from different studies in 
meta-analyses. This is a crucial characteristic, because extremely large numbers of samples 
are required, in order to detect the small effects of many common variant on complex 
diseases. It is worth to notice that in GWAS, up to 5 million SNPs can be simultaneously 
tested raising the issue of false positive due to multiple testing. For achieving an effective p 
value of 0.05 the genome-wide significance threshold is usually set at approximately 10-8. [5] 
GWAS for addiction is in a relatively early stage, with missing of several addictions to be 
evaluated and the number of samples that have been studied so far have either not been 
very large (<10,000) or have been flawed by cross-country heterogeneity, having less than 
optimal phenotying and insufficient number of subjects with an extreme phenotype. [5] 
So far, the strongest and confirmed locus detected by GWAS is for the CHRNA5-
CHRNA3-CHRNB4 gene cluster on chromosome 15q25. This region harbors a locus-
altering tendency to nicotine addiction. Association of genetic variation, within this region, to 
smoking behavior was initially discovered using a candidate gene approach but was 
subsequently replicated by GWAS. [5] 
Since the development of high-density microarray technology, it has become possible to 
identify a large number of single nucleotide genetic variants in a single individual. Statistical 
analyses comparing groups of individuals using these high-density microarrays have allowed 
researchers to conduct genome-wide association studies. These studies have provided 
confirmatory evidence for the involvement of previously identified genetic variants and the 
genes containing these variants, as well as evidence for the involvement of genes and 
genomic regions that have not been previously associated with addictions. [18] 
However, the impact of less common variants cannot be assessed by using the current 
GWAS arrays and requires sequencing strategies. It is important to note that the technology 
for finding genomic variations is changing rapidly. Chip-based genotyping platforms, such as 
those mentioned above, will be most probably replaced over the next years with new 
technologies for sequencing the entire genome. These next-generation sequencing methods 
will provide all the DNA sequence variation in the human genome. [19] 
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Since the completion of the first human genome sequence in 2003, demand for cheaper and 
faster sequencing methods has markedly increased. This demand led to the development of 
next-generation sequencing (NGS). [18] 
NGS data output has increased since it was invented. In 2007, a single sequencing run could 
produce a maximum of around one gigabase (Gb) of data and by 2011 that rate had nearly 
reached a terabase (Tb). [21, 22] 
During the past decade, several platforms have been developed. NGS platforms perform 
massively parallel sequencing and this technology facilitates high-throughput sequencing, 
which allows an entire genome to be sequenced in less than one week. However, data 
analysis may take several weeks, for analyzing the variants in 3 billion base pairs and its 
significance is sometimes difficult to establish. [18] 
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5. Dependence and Genetic Factors 
 
5.1 Genetic markers of alcohol addiction 
 
Alcohol dependence is characterized by a cluster of cognitive, behavioral, and physiologic 
symptoms, with and affected individual continuing to drink, despite significant alcohol-
induced impairment or distress. [23] 
Alcohol drinking is highly prevalent in many cultures and contributes to the global burden of 
disease. In fact, it is linked to more than 60 diseases, including cancers, cardiovascular 
diseases, liver cirrhosis and neuropsychiatric disorders and the World Health Organization 
estimates that approximately 76.3 million people have alcohol-linked disorders, besides car 
accidents in consequence of alcohol abuse. [24, 25] 
On a population basis, alcoholism alone subtracts an average of 4.2 disability adjusted life 
years (DALYs), which are the years of life that are lost due to premature mortality or 
disability, per person; tobacco subtracts 4.1 DALYs and illicit drugs subtract 0.8 DALYs. For 
comparison, AIDS subtracts 6.0 DALYs and type 1 diabetes subtracts 0.1 DALYs. [15] 
Alcohol shares in common with nicotine, cocaine, amphetamine, heroin and morphine, the 
property of enhancing dopamergic transmission in ventral striatum and medial prefrontal 
cortex. This release of dopamine is partially enhanced by stimulation of μ-opioid receptors 
(for which endorphin is the primary ligand) located on inhibitory GABAergic interneurons in 
the VTA. [26] 
The GABAergic interneurons inhibit the dopaminergic ventral tegmental neurons, whose 
activation signals the reward launch. Thus, μ-opioid receptor agonists enhance the likelihood 
of ventral tegmental dopaminergic neuron activation (and the experience of reward) by 
lessening the tonic inhibition of the associated GABAergic interneurons. [26] 
Endorphin elevations after alcohol intake are seen in discrete reward regions of the 
hypothalamus, ventral tegmentum, and ventral striatum. [26] 
In the 1980s, a substantial evidence was developed that naltrexone, an orally active μ-opiod 
receptor antagonist, could decrease alcohol self-administration, craving and relapse to heavy 
drinking, but did not reduce abstinence rates. There have been more than 30 clinical trials of 
naltrexone in alcohol addiction showing the efficacy of naltrexone in reducing risk for 
relapse to heavy drinking, although the effect size is small, with many patients having no 
benefit. These results confirmed the neurobiological effects of alcohol in reward circuits 
related to opioids. [26] 
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A meta analysis, which included 9,987 monozygotic and dizygotic twin pairs, estimated a 
heritability of alcoholism to lie around 50-60%. [15] 
Researchers have identified several genes that predispose individuals to developing alcohol 
dependency and encode for proteins that play a role in the pharmacokinetics and 
pharmacodynamics of ethanol; alterations in these factors alter the rewarding effects of 
alcohol, thereby affecting its abuse liability [25] 
A common missense single nucleotide polymorphism (rs#1799971) in the first exon of the 
μ-opioid receptor gene, OPRM1, was described in 1997, c.118A>G, or p.N40G, reflecting 
the fact that the A allele encodes asparagine, whereas the minor G allele encodes aspartate. 
Subsequent studies revealed large ethnic differences in allele frequencies (see Table 3). [26] 
 
 
 
 
Table 3: Frequency of G allele for c.118A>G SNP in ethnic groups (adapted 
from Berretini, 2013) 
Ethnic Group Frequency of G Allele 
African 1% 
African-American 3% 
European-American 15% 
Chinese 35% 
 
 
Many studies have been carried out in order to understand the functional consequences of 
this allelic variant. Beyer et al. (2004) reported that the 118G allele was not different from 
the 118A allele in rate of internalization, but 118G had decreased transcription, compared to 
118A. Similar results were obtained by Zhang et al. (2005) that revealed a marked decrease 
in 118G allele mRNA. [26] 
In a laboratory investigation of c.118A>G pharmacogenetics, related to alcohol reward in 
humans, Ray and Hutchison (2004, 2007) showed that the G allele carriers experienced 
significantly stronger euphoria sensation after standard oral doses of alcohol, compared to 
AA individuals. In agreement with this result, Ramchandani reported that G allele carriers 
had a higher striatal release of dopamine after alcohol (using detection of raclopride binding 
to DA receptors by PET scan), compared to AA participants. These laboratory studies of the 
human c.118A>G variant on effect of alcohol are remarkably consistent, with the clear 
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conclusion that the G allele allows people to experience alcohol in a more rewarding 
manner, compared to AA individuals. [26] 
Multiple neurotransmitters are involved in orchestrating ethanol’s reward profile, including 
dopamine, γ–aminobutyric acid (GABA), glutamate, and serotonin. Ethanol has been shown 
to enhance the function of γ–aminobutyric acid receptor type A (GABAA), neuronal α2β4 
nicotinic acetylcholine, and glycine receptors, and to inhibit N-methyl-d-aspartate-(NMDA) 
type glutamate receptor function. The polymorphism c.1236C>T, in the gene that encodes 
the α6 subunit of the GABAA receptor, has been associated with a low level of response to 
alcohol, which is a strong predictor of developing alcohol dependency. Other SNP 
haplotypes in the gene encoding the α1 subunit have also been detected at higher 
frequencies in alcohol-dependent individuals. [25] 
Alcohol dehydrogenase (ADH) metabolizes ethanol to acetaldehyde, a toxic intermediate, 
which is then metabolized to acetate by aldehyde dehydrogenase (ALDH). Variations in the 
genes encoding these enzymes can alter alcohol metabolism and result in the accumulation 
of acetaldehyde during alcohol consumption, which causes a flushing response as well as 
headache, nausea, and palpitations. Functional polymorphisms in multiple alcohol 
dehydrogenase coding genes, namely ADH4, ADHIB, and ADHIC, as well as the aldehyde 
dehydrogenase coding gene ALDH2, have been shown to alter the risk for developing 
alcohol dependency. Twelve SNPs in and around the ADH4 gene have been consistently 
associated with a higher risk for alcohol dependency in a variety of populations. In particular, 
the -136C>A polymorphism in the promoter region of ADH4 has been extensively studied. 
The -136A allele has been associated with an increased susceptibility to alcohol dependency. 
The -136A allele, associated to higher activity, caused a lower peak blood ethanol level after 
alcohol ingestion, compared to the -136C allele. The ADH1B*2 variant was associated with 
increased ethanol oxidation to acetaldehyde and has been shown to protect against alcohol 
dependency in a variety of populations. [25] 
The enzyme Cytochrome P450 2E1 (CYP2E1) also participates to the metabolism of ethanol, 
mainly in liver. CYP2E1 accounts for approximately 20% of ethanol metabolism at low blood 
concentrations, and its contribution increases to 60% at high concentrations. CYP2E1*1D 
has been shown to have increased enzymatic activity and has been associated with alcohol 
dependency, although inconsistent results have been obtained across studies. The 
CYP2E1*5B polymorphism has been associated with altered transcriptional activity of the 
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CYP2E1 gene. CYP2E1*5B has been associated with higher ethanol consumption and risk for 
alcohol dependency. [25] 
Twin and adoption studies suggest that familial pattern of alcohol dependence may be 
attributable to additional genetic factors, which account for roughly 40-60% of the liability 
for this addiction. [27] 
Due to the etiological complexity of complex traits like alcohol dependence, newer DNA 
sequencing methods, in particular, next generation sequencing (NGS) have become 
increasingly useful as they provide a more accurate description of both common and rare 
variants. So far, molecular genetic studies have linked variations across chromosomes 1, 2, 3, 
4, 7, and 8 to diagnoses of alcohol dependence, as well as chromosomes 5, 6, 9, 15, 16, and 
21, using quantitative phenotypes (e.g., maximum number of drinks) and neurophysiological 
phenotypes that are often comorbid with alcohol dependence and other psychiatric 
disorders. To date, at least one variant in about 602 genes has been linked to alcoholism 
and/or alcohol dependence. [27] 
Pharmacogenetic research has also shown that variations within ADH and ALDH genes may 
alter a person’s risk for developing alcohol-linked problems. For example, of the seven genes 
that code for different forms of ADH (clustered on chromosome 4q), variants within the 
genes encoding the hepatic isoforms, ADH1B and ADH1C have been related to alcohol  
dependence. The ADH1B*2 allele has also been shown to have a protective role against 
alcoholism in males and females of different ethnic origins. [27] 
Concerning ADH, three class I isoenzymes are known for their genes closely linked, located 
in chromosome 4q22. Three different alleles, ADH1B*2, ADH1B*3 and ADH1C*1, have 
been shown to alter ADH enzymatic activity, with ADH1B*2 and ADH1B*3 increasing the 
activity more than 30-fold. As individuals carrying these alleles are likely to have a higher 
concentration of acetaldehyde, a hypothetical protective effect can be proposed. The allele 
ADH1C*1 is found with a frequency of 55–60% in Europeans. A meta-analysis revealed that 
ADH1B*2 has protective properties decreasing the risk of alcoholism by a factor of 3, 
compared to the ADH1B*1 allele. [28] 
As a consequence of genotyping 110 SNPs throughout the ADH gene cluster, located on 
chromosome 4, the results revealed twelve SNPs in ADH4 gene and sorroundings that were 
significantly associated with alcoholism. It was also shown that there was a modest evidence 
of association with SNPs in ADH1A and ADH1B, suggesting that alleles of these genes 
contribute to alcoholism susceptibility. From nine gene families encoding for human ALDH, 
only ALDH1 and ALDH2 are centrally involved in the oxidation of acetaldehyde; ALDH2 
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plays the major role in the acetaldehyde oxidation. The ALDH2*2 allele is associated with 
enzyme inactivity resulting in symptoms of acetaldehyde syndrome. Therefore, ALDH2*2 
seem to reduce the risk of becoming alcohol dependent by 10-fold, thus providing a stronger 
protective effect as compared to alterations reported in ADH1B and ADH1C genes. [28] 
Approximately 45% of East Asians (Japanese, Chinese, Koreans) are carriers of the 
ALDH2*2 allele (Glu504Lys, rs#671) that leads to the inactive ALDH2 enzyme. After 
consumption of small quantities of alcohol by these individuals, the endotoxin acetaldehyde 
rapidly accumulates, resulting in the very unpleasant flushing syndrome (facial flushing, 
tachycardia, sweating, headaches, nausea), colloquially called ‘Asian Glow’ or ‘Asian Blush’, 
that is protective against heavy drinking and therefore alcoholism, related to the unpleasant 
physiological features mediated by acetaldehyde. [29] 
The two examples of verified human “addiction genes” encode for enzymes that catalyse 
consecutive steps in alcohol metabolism, as ADHIB and ALDH2. The most important loci at 
these genes are p.His47Arg in the ADH1B gene and p.Glu487Lys in the ALDH2 gene. Either 
higher activity of ADH1B (conferred by the His47 allele) or lower activity of ALDH2 
(conferred by the Lys487 allele) leads to accumulation of acetaldehyde after alcohol 
consumption, which causes the aversive flushing reaction described above. The genotype-
associated flushing is equivalent to the effects of disulfiram that inhibit ALDH. In several 
eastern countries, such as Japan, where both His47 and Lys487 are highly abundant, most of 
the population carries a genotype that is protective against alcoholism. [15] 
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Table 4: Evidence of the genetic influence on alcohol consumption from genetic studies: 
summary of results of ADH genes (adapted from Köhnke (2008)) 
Examined 
Polymorphism/ 
Chromosomal 
region 
Examined phenotype Method Reference 
ADH1B*2 Protective against alcohol 
dependence 
Case 
control 
Shen YC, 1997 
ADH1B*2 Protective against alcohol 
dependence 
Meta-
analysis 
Whitfield JB, 1998 
ADH1B*2 Reduced level of weekly peak 
alcohol intake 
Case 
control 
Neumark YD, 1998 
ADH1B*2 Protection against alcohol related 
birth defects 
Case 
control 
Viljoen DL, 2001 
ADH1B*3 Protection against alcohol related 
birth defects 
Case 
control 
McCarver DG, 1997  
ADH1B*3 Negative family history of 
alcoholism 
Case 
control 
Ehlers CL, 2001 
ADH1B*3 Protective against alcohol 
dependence 
Linkage 
analysis 
Edenberg HJ, 2006 
ADH1C*2 Protective against alcohol 
dependence 
Case 
control 
Shen YC, 1997 
ADH4 AC Alcohol dependence Case 
control 
Guindalini C, 2005 
ADH4 SNP2, 
SNP3 
Alcohol dependence Family- 
based 
association 
Luo X, 2005 
SNPs: 
chromosomal 
region 4q21-
23 
Alcohol dependence Linkage 
analysis 
Reich T, 1998; Long JC, 
1998; Prescott CA, 
2006; Edenberg HJ, 
2006 
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GABA is the major inhibitory neurotransmitter in the central nervous system. GABA A 
receptors are sensitive to ethanol in distinct brain regions and are clearly involved in acute 
actions of ethanol, ethanol tolerance and ethanol dependence. [28] 
A linkage study revealed evidence of linkage to a chromosomal region on chromosome 4p 
near the β1 GABA receptor gene (GABRB1), a finding that was confirmed by an association 
study which revealed a significant association between GABRB1 and alcoholism. [28] 
A German consortium, Genetics of Alcohol Addiction, which aims to identify and validate 
candidate genes and molecular networks involved in the aetiology of this pathology, 
published the first GWAS for alcohol dependence. One goal of this systems genomic 
approach is to provide an understanding of the complex mapping relationship between the 
genome and disease, by investigating intermediate endophenotypes. By genotyping a dense 
set of SNPs throughout the genome, researchers have the potencial to identify with 
considerable precision genes involved in alcohol dependence. [24, 30] 
This GWAS was performed in 487 patients and 1,358 controls, allowing identification of 121 
SNPs with nominal p<0.0001 and these SNPs were genotyped in the follow-up sample. As a 
result, fifteen SNPs showed significant association with the same allele as in the GWAS. In 
the combined analysis, two closely linked SNPs in the 3´flanking region of the peroxisomal 
trans-2-enoyl-coA reductase (PECR) gene, achieved genome-wide significance (rs#7590720; 
rs#1344694). [24] 
Treutlein and colleagues (2009) conducted a GWAS and follow-up study for alcohol 
dependence using individual genotyping in a German male sample. In total, 139 SNPs were 
carried forward for genotyping in the follow-up study and three genes were confirmed to be 
associated to alcohol consumption: alcohol dehydrogenase 1c (ADH), cadherin 13 (CDH) 
and gata-binding protein 4 (GATA). Two markers, rs#7590720 and rs#1344694, remained 
significant after genome-wide correction in the combined sample of 1,460 patients. The two 
markers are located approximately 5 kb apart in chromosome region 2q35, which has been 
implicated in linkage studies for alcohol dependence phenotypes. Linkage to this region was 
found in a genome-wide search in 2,282 individuals from 262 families with a high prevalence 
of alcohol dependence in the Collaborative Study on the Genetics of Alcoholism (COGA). 
[23] 
Candidate gene strategies have identified significant associations between SNPs in the gene 
encoding the alpha2-subunit of the γ-aminobutiric acid A receptor (GABRA2) and there are 
multiple positive reports of association between SNPs in GABRA2 and alcohol abuse 
phenotypes. [30] 
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Bierut et al. (2010) reported on a large sample of 1,897 alcohol dependent cases from the 
“Study of Addiction” (Genetics and Environment analysis of 948,658 SNPs that span the 
genome). Primary analysis from GWAS identified 15 SNPs with p<10-5 and the top 
associated SNPs were tested for replication in two independent datasets. The first 
replication sample is the family-based study from the Collaborative Study on the Genetics of 
Alcoholism (COGA) and none of the SNPs showed association with a p<0.05; however, 
rs#1386449 and rs#10224675, which in the primary analysis were associated with alcohol 
dependence only in African-Americans have a p<0.10 in the family based analysis with a small 
number of African-American families. Of the seven SNPs that were genotyped, for none a 
significance level of p<0.05 was reached. [30] 
Only one SNP (rs#13160562) shows modest evidence of replication for SNPs reported in 
the independent GWAS of alcohol-dependent men by Treutlein et al. (2009). In a meta-
analysis, this SNP did not reach genome-wide significance (OR= 0.83, 95% CI 0.77-0.90, 
p=2.74x10-6). [30] 
This analysis confirms the modest association of alcohol dependence with variants in 
GABRA2. The two genome-wide significant results reported by Treutlein and colleagues, 
rs#7590720 and rs#1344694, were not replicated in this study. [30] 
In addition to the possibility that some of the top signals were false positives, the high levels 
of comorbid substance-use disorders may have increased the odds to identify association to 
genes contributing to addiction in general and may potentially limit the ability to replicate 
these association results in samples ascertained solely for alcohol dependence. [30] 
Advantages of the genome-wide design include its hypothesis-free strategy and its suitability 
for the discovery of novel genetic contributors to disease. However, the genome-wide 
examination requires correction for multiple testing and the threshold for significance of 
GWAS findings is high. On the contrary, targeted gene studies test specific hypothesis to 
provide validation of previously reported findings and require much lower threshold for 
significance. [30] 
To increase the power to detect significant results, two strategies can be taken: enlarge the 
sample or to narrow the phenotype to increase the detectable genetic effect. [30] 
Gelernter reported a GWAS of alcohol dependence in European-American (EA) and 
African-American (AA) populations, with a total sample of 16,087 subjects. GWAS was used 
in order to identify genetic variants that influence risk of AD as both a diagnosis and an 
ordinal trait in EA and AA subjects. In ordinal trait analysis, the genome-wide association 
results for numerous variants were significant. The highest number of significant findings map 
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to the region of the ADH gene cluster in chromosome 4. There is a strong evidence for 
association with LOC100507053 (a lncRNA gene) and ADH1B in both AAs and EAs, most 
notably ADH1B SNPs rs#1229984 (p=1.14x10-6) in EAs and rs#2066702 (p=3.20x10-5) in 
AAs. In EAs, the association with rs#1229984 was observed previously by Bierut et al. 
(2010), but with a much weaker significance. The finding with rs#1789882 is the first GWAS 
finding for alcohol dependence in AAs, although the risk locus was known previously. [31] 
In their study, Gelernter et al. (2014) identified a novel genome wide association (p=5.57x10-
10) with rs#1437396, which is located between and within 10kb of MTIF2 (mitochondrial 
translational initiation factor 2) and CCDC88A (coiled-coil domain containing 88A) on 
chromosome 2, a risk locus that was supported by evidence obtained from analysis of both 
the EA and AA samples. It interacts with DISC1, a gene originally known to be as a 
schizophrenia risk locus, but association with opioid dependence has also been show. [31] 
The GWAS approach to alcohol dependence suggests that this a genetically heterogeneous 
dependence; however, some candidate genes have been validated, as the ADH1C gene. 
GWAS of alcohol dependence and related phenotypes have identified numerous loci, but 
these loci alone have limited usefulness, once each one accounts for less than 1% of the 
variance in liability. Despite this alcohol GWAS continue to be studied because it support 
pathways that were hypothesized from linkage study findings and also highlight pathways that 
were not initially considered. [27] 
Several new challenges arise from the fact that hundreds of genetic variants, each with a 
modest effect, contribute to its liability. Challenges, such as the identification and selection of 
polymorphisms, the reduction of the heterogeneity of alcohol phenotypes and the 
development/ implementation of the mathematical approaches and a conceptual framework 
will provide power and a meaningful interpretation of the findings. [27] 
Missing heritability in GWAS has been attributed to the emphasis on common genetic 
variants that have low penetrance. As the number of variants tested on GWAS evolved from 
testing thousands of variants to more than 1 million, the likelihood of capturing variants that 
are in linkage disequilibrium with rare variants has increased. These observations suggest 
that when treated individually, common variants, such as SNPs, account for a small fraction 
of the missing heritability. The most likely solution to this problem would be the 
incorporation of both common and rare genetic variants using whole genome sequencing 
platforms. [27] 
Missing heritability of GWAS in alcohol dependence can also be attributable to the fact that 
the liability of the disease is genetically and phenotypically heterogeneous. This reflects the 
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fact that people become addicted for different reasons. The lack of power of GWAS in 
alcohol dependence may be explained by the use of phenotypes that fail to capture the 
biological underpinnings of the pathology, which would lead to the classification of groups of 
alcoholics that may be more genetically homogenous. [27] 
Alcohol dependence genetic complexity highlights the need for comprehensive models. 
System-based genetic studies of AD have become increasingly possible because of the major 
advances in genomics, proteomics, gene vs. environment interaction and correlation studies, 
and epigenetics. The combination of DNA whole genome genetic variations, with epigenetic, 
transcriptomic and proteomic profiles, taken from selected neuronal tissues involved in 
different stages of addiction, would be the ideal approach to achieving systems-based models 
for alcohol dependence. [27] 
 
 
5.2 - Genetic markers of cocaine addicition 
 
Cocaine is a central nervous system stimulant that acts primarily at the dopamine 
transporter DAT1, preventing dopamine uptake into presynaptic terminals and increasing 
synaptic dopamine levels. The susceptibility to cocaine dependency has been associated with 
variations in the genes involved in monoaminergic transmission. [25] 
The profound loss of behavioral control is the Hallmark of cocaine addiction and contributes 
to the high risk of relapse. [33] 
The psychostimulant properties of cocaine stem from its ability to inhibit reuptake by DAT1, 
but also acts at serotonin, and norepinephrine transporters, leading to the increase in 
neurotransmitters’ synaptic levels. [34] 
While the interplay between genetic and environmental factors underlying cocaine 
dependence is not fully understood, several studies have estimated that approximately two 
thirds of an individual’s risk for developing this addiction is heritable. [33] 
Identifying genetic risk factors is difficult due to the complex mode of inheritance, as well as 
clinical and genetic heterogeneity of cocaine-dependent individuals and strong environmental 
influences. Furthermore, associated genetic variations may be only a small contribute to the 
overall risk. Twin and family studies have demonstrated that cocaine addiction has a strong 
genetic component but the exact basis of the heritable factors that have a significant 
contribution to this phenotype remains unclear. [33, 35] 
Pharmacogenomics of Drug Addiction 2014 
 
32 
 
Genes involved in dopamine neurotransmission are biologically plausible candidate genes for 
cocaine addiction, since dopamine pathways play a major role in drug reward effect. 
Specifically, genes for dopamine receptors and transporters are logical targets for study, 
since they are directly responsible for transmitting dopamine-mediated brain signals. [33] 
Cocaine addiction is accompanied by a decrease in striatal dopamine signaling, measured as a 
decrease in DRD2 binding as well as blunted dopamine release in the striatum. These 
alterations in dopamine neurotransmission have clinical relevance, and have been shown to 
correlate with cocaine-seeking behavior, as well as with response to treatment for cocaine 
dependence. [36] 
The DRD2 gene encodes an inhibitory dopamine receptor subtype. The striatopallidal 
medium spiny neurons, the cells involved in psychostimulant reward pathways, 
predominantly express this dopamine receptor subtype. Hence, variations in the DRD2 gene 
may affect dopamine signaling via the striatopallidal pathway and, consequently, increase 
susceptibility to addiction by cocaine. While many single nucleotide polymorphisms (SNPs) 
spanning in the DRD2 gene are cataloged, such as the TaqIA SNP (rs#1800497) has been 
shown to affect directly dopamine binding with DRD2. Furthermore, this polymorphism has 
been previously implicated in drug addictions such as heroin dependence and alcoholism. 
Therefore, the TaqI A SNP in the DRD2 gene is probably a biologically functional candidate 
variant underlying susceptibility to cocaine dependence. [33] 
Another plausible susceptibility gene for C is SLC6A3, coding for the dopamine transporter 
gene DAT1. The DAT1 protein mediates the active dopamine reuptake from the synaptic 
cleft into the presynaptic terminals, regulating the duration and intensity of dopaminergic 
signaling. Cocaine’s pleasurable and addictive effects are thought to be mainly mediated 
through the blockage of DAT1, substantially increasing the concentration of extracellular 
DA, resulting in elevated stimulation of neurons involved in reward and reinforcement 
behavior. [33, 37] 
Like DRD2, DAT1 is expressed in the striatal neuroanatomical region, which is implicated in 
cocaine reward. Many polymorphisms across the SLC6A3 gene have been identified. The 
variable number tandem repeat (VNTR) polymorphism in the 3’ region of SLC6A3, consists 
of a 40-bp repetitive sequence, which results in lower expression of the dopamine 
transporter in the putamen. It has been reported that the 10-repeat allele (10R) enhances 
the expression of the DAT1 protein while another study claimed that the 9- repeat allele 
(9R) enhanced the SLC6A3 transcription and DAT1 expression. Although the specific results 
of each study conflicted, both reports suggest that the SLC6A3’_VNTR polymorphism affects 
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DAT1 expression, consistent with subsequent findings that this VNTR is associated with 
drug addictions such as methamphetamines and alcoholism. [25, 33] 
 A 40-bp VNTR in the 3’ terminal, which results in lower expression of the dopamine 
transporter in the putamen, was shown to affect a variety of smoking behaviors and the risk 
for cocaine-induced paranoia. [25] 
Both DRD2 and SLC6A3 have been investigated in cocaine addiction and positive 
associations have been found among Caucasian European and Brazilian populations. [33] 
A brazilian study examined the functional influence of genetic SLC6A3 variants on DAT1 
expression, related to cocaine addiction and repeat polymorphisms were genotyped in 
cocaine-dependent abusers (n=699), including a 30-bp VNTR in intron 8 (Int8 VNTR). Their 
results revealed that the 3’ UTR VNTR is not unique and there are approximately 15 other 
candidate simple tandem repeats and VNTRs in the introns of SLC6A3 with at least six 
copies. Guindalini et al. (2006) identified a positive association between the 30-bp VNTR in 
Int8 of the DAT1 and cocaine abuse. [37] 
Another study in a Spanish sample (n=169) that aimed to analyze several polymorphisms in 
SLC6A3 (VNTRs in the 3’ untranslated region, 3’UTR, and in intron 8), DRD2 (TaqIA and 
TaqIB SNPs in 3’UTR and in intron 1) and in the gene coding for one enzyme of dopamine 
biosynthesis, DA beta-hydroxylase, DBH (19-bp insertion/deletion in 5’UTR and c.444G>A 
in exon 2) showed no significant association was found between cocaine dependence and the 
3’UTR VNTR of DAT1, the TaqIA and TaqIB of DRD2 and the 19-bp insertion/ deletion and 
c.444G>A of DBH. Despite these results, a nominal association between cocaine 
dependence and the 5R/5R genotype of the Int8 VNTR within the DAT1 gene was found. 
[38] 
These conflicting results highlight the need for more extensive association studies in terms 
of sample size and genetic coverage. [38] 
The enzyme DBH catalyzes the conversion of dopamine to norepinephrine (NE) and could, 
therefore, have an influence on both cocaine action and the basal sensitivity of 
neurotransmitter systems to cocaine. It has been demonstrated that DBH knockout mice 
are hypersensitive to the psychomotor, rewarding, and aversive effects of cocaine. 
Pharmacological treatment studies with the DBH inhibitor disulfiram also indicate that this 
medication has efficacy as a treatment for cocaine dependence. [39] 
DBH plasma activity levels were reported to vary widely among individuals. Cubells and 
colleagues (2000) found that a 19-bp insertion/ deletion polymorphism and the SNP 
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c.444A>G were associated with plasma DBH levels and that alleles of similar results for 
association to enzymatic levels were in significant positive disequilibrium. [40-42] 
Guindalini et al. (2008) conducted an association study with a sample of 689 cocaine addicts 
to verify the influence of c.1021C>T polymorphism on the susceptibility to cocaine 
addiction. Genotypic and allelic distribution did not provide any evidence for association 
with cocaine addiction. [39] 
Cocaine is also known for its effect of blocking serotonin reuptake from the synaptic cleft 
through the binding to the serotonin transporter 5HTT, which increases the level of this 
neurotransmitter at the neuronal synapses. [40] 
Since altered 5-HT transmission is thought to increase susceptibility to dependence it is 
reasonable to question if polymorphisms in the 5HTT gene may contribute to the individual’s 
risk for addiction, disease progression and response to treatment. The most studied 
functional polymorphisms of the 5HTT gene are the 5HTT-LPR (serotonin-transporter-
linked polymorphic region) at the promoter region, which contains 14 (short, S) or 16 (long, 
L) copies of a 22-23 bp repeat element, and the 5HTT-VNTR in intron 2, with four variants 
containing 9-12 repeats of a 16-17 bp unit (9R-12R). [40] 
A recent study in vitro demonstrated that 5HTT-LPR and 5HTT-VNTR modulate the 5HTT 
transcription in response to cocaine by altering the binding of different transcription factors 
and inducing chromatin modifications. Gene reporter experiments showed that the LPR-
VNTR haplotypes S-12R and L-10R increased by two or six fold, respectively, the basal 
transcription levels in the presence of cocaine in vitro. [40, 43, 44] 
A case-control association study conducted in a Spanish sample (n=504) aimed to evaluate 
the correlation between haplotype combinations of the 5HTT S-12R and L-10R 
polymorphisms and the expression of the serotonin transporter after cocaine exposure. This 
study showed no evidence of an overrepresentation of any of these allelic combinations and 
no differences were observed neither in the presence or absence of psychotic symptons or 
comorbid dependence to other drugs. [40] 
 
 
5.3 Genetic markers of opioid addiction 
 
The effects of opioids and opiates are mediated primarily through the endogenous opioid 
receptor system, which includes receptors μ-opioid (MOR), δ-opioid (DOR), and κ-opioid 
(KOR). These three receptors are mainly expressed in the central and peripheral nervous 
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systems. Growing evidence from different reports has shown that these three opioid 
receptors mediate the analgesic effect and addictive properties of opioid drugs. Stimulation 
of MOR by opiates of abuse or endogenous ligands (e.g., enkephalins, endomorphines and 
dynorphins) inhibits transmission through the inhibitory GABA neurotransmitter system, 
thereby resulting in a disinhibition of the mesolimbic mesocortical dopamine pathways. [25, 
45, 46] 
Heroin and prescription opioids, such as oxycodone or hydrocodone, act primarily as MOR 
agonists with relatively short duration of action. [47] 
The main active metabolites of heroin also act primarily as MOR agonists. Heroin enters the 
brain quickly and in high concentration. Once in the brain, heroin is rapidly converted to the 
biologically active metabolites morphine and monoacetylmorphine. This conversion may also 
occur in liver, in the first passage metabolism. These compounds bind MOR and relieve 
GABAergic inhibition of dopamine neurons. [47] 
Methadone is a full MOR agonist and a weak NMDA receptor antagonist. Methadone 
metabolism is mediated by cytochrome P450 enzymes CYP3A4, CYP2B6 and CYP2D6. [47] 
Opioid receptors have been the main focus of addiction research due to the its involvement 
in drug reward pathways. The rewarding effects of drug use are mediated by MOR and DOR 
activation, whereas KOR activation is mainly associated with aversion. [45] 
Genes coding for proteins known to be involved in the pathophysiology of specific drug 
dependences are good candidates for genetic association studies of these neurodegenerative 
disorders. Genes encoding opioid receptors (OPRM1, OPRD1 and OPRK1, which encode 
the μ-, δ- and κ- receptor, respectively) are among the most obvious candidates for 
investigating opioid dependence, but also other forms of substance abuse and addiction. [46] 
The μ-receptor has been considered the primary target for opioid addiction and it has the 
highest affinity for morphine and its stimulation leads to pain relief and euphoria. Because the 
μ-opioid receptor is the primary target of opiates, genetic variations affecting its function 
became an important area of study when assessing the effects of pharmacogenetics on opiate 
addiction. Although MOR is considered the primary target for the rewarding effects of 
addiction, there are many MOR interacting proteins (MORIPs) that may modulate MOR 
function, among other factors. One of these MORIPs is DOR, suggesting that genetic 
variation in OPRD1, the gene encoding for DOR, may affect susceptibility to drug addiction. 
[25, 45, 46] 
The MORIPs include opioid ligands and heterotrimeric G-proteins, which control receptor 
activation and downstream signaling, respectively. Other MORIPs are known to prevent 
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activation of MOR signaling or regulate the desensitization of MOR by blocking access to 
specific protein binding domains. The Wntless (WLS) homolog (Drosophila) protein was 
identified as a MORIP type of molecule, which is useful for model studies. A case-control 
association analysis has been performed to determine if common variants in the human WLS 
gene were associated with opioid or cocaine addiction in African-American and European-
American populations. Nominally significant associations were found between 3 SNPs and 
opioid addiction. In the African-American population rs#3748705 was associated with 
addiction and rs#983034and rs#1036066 showed positive association in the European-
Americans. None of the results for these SNPs were significant after false discovery rate 
(FDR) correction. [45] 
Many functional variants have been identified in the OPRM1, being the most common 
c.118A>G (rs#1799971) in the coding region, exon 1, which causes the replacement of an 
asparagine residue by aspartic acid. The Asp40 residue results in a three-fold increase in β-
endorphin binding compared with the asparagine’s containing protein. The c.118G allele is 
most common in Asian populations (40-50%) and has a moderate frequency in European 
populations (15-30%), with very low prevalence in African populations. It has been shown 
that the c.118G allele is positioned within a haplogroup in a population-specific manner and 
is in high linkage disequilibrium (LD) with several distant variants that may have regulatory 
effects. Carriers of the c.118G allele show an elevated sensitivity to pain and reduced 
analgesic response to opioids. Homozygotes for this allele tend to need higher doses of oral 
morphine in treatment for cancer pain. [25, 47, 48] 
A number of studies have reported positive associations between OPRM1 functional variant 
c.118A>G and dependence of opiates, cocaine or alcohol. However, a meta-analysis that 
included the study of 28 samples showed no evidence for an association of this 
polymorphism with substance addiction. Although there was significant evidence of an 
association of substance dependence in some studies, the contradictory nature of the results 
from different authors complicates the interpretation and clinical biomedical significance of 
results. An alternative explanation is that the c.118A>G polymorphism is in linkage 
disequilibrium with another genetic alteration that conveys the primary effect on 
susceptibility to addiction. However haplotype analyses have also failed to yeld consistent 
findings. [45, 48] 
The second most prevalent variant of the OPRM1 is the c.17C>T SNP in the coding region, 
and it is found at frequencies that range from 0.5%–21% across different populations, but it 
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has been found mostly in populations with African ancestry. This SNP has been associated 
with a higher risk for opiate dependency. [25, 47] 
The κ-opioid receptor gene (OPRK1) has also been implicated in response to opiates, and 
multiple variants in the gene have been reported. Preliminary evidences suggest that the SNP 
c.36G>T (allele T with frequency of 1–3% in Europeans) may be associated with an increased 
risk for opiate addiction. [25] 
Although the primary actions of the δ-opioid receptor (coded y OPRD1 gene) manifest in 
nociception, some of its function lies in modulating the effects of μ-opioid receptor-directed 
opiates. Two coding variants of OPRD1 have been studied for association with drug 
addiction: c.80G>T (rs#1042114) in exon 1 and c.921C>T (rs#2234918) in exon 3. The SNP 
c.80G>T was significantly associated with a higher likelihood of opioid dependency, and the 
haplotype that contains both SNPs c.80G>T and the c.921C>T had a significant risk effect on 
opioid dependency. [25, 45] 
Mayer et al. (1997) reported a positive association between OPRD1 c.921T>C and heroin 
addiction in a German population. These authors have found that both the C-allele and the 
C/C homozygotes were significantly more frequent in a sample of 103 German Caucasian 
heroin addicts, compared to control subjects. However, Franke et al. (1999) used both case-
control and family-based designs in another German population, but found no evidence for 
association or linkage disequilbrium of the same variant with heroin or alcohol dependence. 
[46, 49, 50] 
Zhang et al. (2008) analysed a sample of 1,063 European American subjects and reported 
that OPRD1 variant c.80G>T in exon 1 may be associated with opiate dependence, since 
c.80G-allele was significantly more frequent in opiate dependent cases (21%) than in controls 
(13.2%). The high frequency of this allele in opiate dependent cases demonstrates that it 
could be a genetic risk factor for the disorder. Moreover, marker OPRD11, which is located 
in the 5´-region and is 2,289 bp distant to c.80G>T, also showed a positive association with 
opiate dependence. Furthermore, the same authors found no evidence for association 
between OPRD1 c.921T>C variant and drug dependence by individual marker analyses and 
thereby were not able to replicate Mayer’s findings. [46] 
Clarke et al. (2013) designed a study aiming to examine the contribution of rare coding 
variants of OPRM1 to the risk for addiction because the majority of the association studies 
analyzing OPRM1 and drug addiction have focused on common variants. These variants have 
an allele frequency above 5% in general population and, when associated with disease, 
typically confer a small to moderate amount of risk. Conversely, the rare variant hypothesis 
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states that a significant proportion of disease risk is due to low frequency variants that 
confer a much higher risk for disease. Rare variants of OPRM1 gene were identified from the 
National Lung Heart and Blood Institute – Exome Sequencing Project and 4 SNPs were 
selected: rs#62638690 and rs#17174794 in European-American subjects and rs#1799971 
and rs#17174801 in African–American subjects. The results showed that of the 2 SNPs 
genotyped in European-American cases, only rs#62638690 was significantly associated with 
drug addiction. The minor allele frequency in cases was 0.38% compared to 0.79% in the 
control population (p=0.02; OR: 0.47 CI 0.24-0.92), suggesting that it may confer a 
protective effect against drug addiction. In African–American cases neither rs#1799971 nor 
rs#17174801 were associated with drug addiction. The total rare variant burden in cases 
both in African–American and African–American was not found to be statistically different. 
[51] 
Epidemiological studies indicate that non-genetic features contribute 40-60% to the risk of 
developing drug addiction. A relevant part of these are environmental and chemical/drug-
induced factors, but other issues, such as epigenetic modifications (DNA methylation and 
chromatin remodeling) may also play an important role. The transmission of information not 
directly encoded in the DNA sequence is termed epigenetic inheritance. DNA methylation 
of cytosine residues in genomic DNA is a common epigenetic mechanism controlling gene 
expression and occurs through the insertion of a methyl group to cytosine residues in 
cytosine:guanine (CpG) dinucleotides by DNA methylation enzymes. CpG dinucleotides are 
often clustered in “CpG islands”. [52] 
Nielsen et al. (2009) reported a study on methylation of CpG sites in OPRM1 gene 
promoter region in former heroin addicts stabilized with methadone treatment. It was found 
that in two of 16 CpG sites in a region of the OPRIM1 gene promoter had significantly 
higher methylation in former heroin addicts than in controls. The two -18 and +204 CpG 
sites that were hypermethylated in the former heroin addicts are located in binding sites for 
the potential Sp1 transcription factor. It is possible that the hypermethylation at these sites 
reduces expression of the OPRM1 gene in former heroin addicts. Future studies may 
determine whether the hypermethylation was due to methadone maintenance 
pharmacotherapy, heroin or if such methylation state might have been inherited through 
genomic imprinting. [52, 53] 
A genome-wide association study approach, which included genotyping 10,000 variants 
simultaneously in 104 former severe heroin addicts and 101 controls, was used to identify 
genetic variants in genes involved in the vulnerability to develop heroin addiction. The 
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authors reported that when allele frequency was analyzed for association with heroin 
addiction, the strongest association was with the autosomal variant rs#965972, located in a 
Unigene cluster of unknown function and in a region predicted to have high regulatory 
potential and with rs#1986513, which is located in a region of high conservation in mammals. 
The three variants exhibiting the strongest association with heroin addiction by genotype 
frequency were rs#1714984, located in an intron of the gene for the transcription factor 
myocardin, rs#965972 and rs#1867898. One haplotype genotype pattern (AG-TT-GG) was 
found to be positively associated with developing heroin addiction (odds ratio= 6.25) and 
explained 27% of the population attributable risk for heroin addiction in this cohort. [52, 53] 
In a hypothesis-driven multi-gene study, 1,350 variants were screened in 130 candidate genes 
in subjects with European ancestry. The case subjects were former severe heroin addicts 
undergoing methadone maintenance treatment. This approach is based on physiological 
hypotheses and the genes were selected based on their function and related pathways. Nine 
variants, in six genes, showed nominal significant associations but none of those remained 
significant after adjustment for multiple testing. These variants were in non-coding regions of 
the genes OPRM1, OPRK1, OPRD1 and , 5HTR3B, among others. [52] 
Gelernter et al. (2013) reported results for a GWAS for opioid dependence in two different 
population groups in the United States. They have also used data from the Study of 
Addiction: Genetics and Environment (SAGE). Several of the top-ranked genes encode 
proteins that participate in potassium and calcium signaling pathways. Although signaling 
related genes have been studied in addiction biology, they were not previously considered 
key candidates for molecular genetic studies. The loci KCNC1 and KCNG2, containing some 
of the most significantly associated SNPs, encode potassium voltage-gated channel subunits. 
Potassium-calcium signaling is involved in coupling neuronal signals to vasodilation in the 
brain and opioids can regulate calcium conductance via increasing potassium conductance in 
MOR receptors. One of the genes in the calcium signaling pathway that is strongly associated 
with opiate dependence risk, CAMK2B, codes for a protein that modulates activation of 
ionotropic glutamate receptors. These pathways may interact to produce biologically 
important effects, both on behavior after an initial exposure to opioids and on impaired 
control over use after chronic exposure. [54] 
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5.4 Genetic Markers of Nicotine Addiction 
 
The development of nicotine dependence is the last step in a sequence of behavioral events 
that starts with the initiation of cigarette use. There are at least three steps in this process: 
the transition from never smoking to the initiation of cigarette use; the conversion from 
experimental smoking to the establishment of regular smoking behavior, and finally the 
development of nicotine dependence among smokers. Each step in this pathway of smoking 
represents a potential point for intervention to prevent the onset of nicotine dependence, 
and different genetic and environmental factors influence the progression through each 
stage. [55] 
Smoking begins with the first cigarette and the next step in the development of dependence 
is the transition from an experimental smoker to a “smoker”, which is defined as an 
individual who has smoked 100 or more cigarettes, a threshold used in many large-scale 
epidemiological studies. [55] 
The progression from smoking to nicotine dependence is influenced by genetic and 
environmental factors. A cluster of symptoms define nicotine dependence, which includes 
tolerance to nicotine (the use of larger amount of substance to obtain the same effect, which 
is consistent with smoking 20 or more cigarettes a day), withdrawal symptons, and use of 
cigarettes despite social restrictions and health consequences. However, not all smokers 
develop nicotine dependence. About half of current smokers are dependent on cigarettes 
and many others have some symptoms of dependence. There is a third group of smokers 
who have no addiction symptoms, a group called “chippers”. In contrast to the nicotine 
dependent smokers who smoke daily and generally are heavy smokers, frequently smoking 
20 cigarettes a day, chippers smoke a few cigarettes a day and may not smoke daily. In 
genetic studies, chippers represent a unique contrast sample to smokers who develop 
nicotine dependence. [55] 
Nicotine is the main reinforcing component of tobacco smoke and is highly addictive. It binds 
and activates the nicotinic acetylcholine receptor in the VTA, which facilitates dopamine 
release in the shell of the NAc, thereby activating the mesolimbic brain reward pathway. 
These receptors are pentameric molecular assemblies of nicotinic acetylcholine receptor 
(nAChR) subunits, which are coded by a family of distinct cholinergic nicotinic receptor 
(CHRN) genes. There is a substantial genetic contribution to various aspects of smoking, 
including initiation, progression, maintenance, amount smoked, and the ability to quit. Twin 
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studies estimated that the heritability of nicotine dependence is approximately 50%. [25, 55, 
56] 
Similar to other diseases with complex etiologies, each gene probably contributes only part 
of the genetic susceptibility to nicotine dependency, and interactions between multiple genes 
ultimately contribute to the risk for smoking. [25] 
Several large-scale studies have identified the region on chromosome 15 that includes genes 
coding for the family of α5α3β4 nicotinic receptors, as being associated with the risk for a 
smoker becoming a nicotine dependent. [55] 
In order to identify alleles associated with nicotine dependence, as number of cigarettes per 
day (CPD) regularly smoked, genetic analysis was conducted in two large European 
populations (~7,500 subjects) using wide genome analysis (WGA) techniques. Berrettini et 
al. (2008) identified independently the same genetic association on chromosome 15, pointed 
by Bierut et al (2009), associating CHRNA3 and CHRNA5 with the risk to nicotine 
dependence. Due to linkage disequilibrium in the CHRNA3-CHRNA5 region, it is possible 
that the causative alleles may lie within either or both of these genes, which code for 
nicotinic receptor subunits. [55, 57] 
Saccone et al. (2009) analyzed 226 SNPs covering the complete family of 16 The CHRN 
genes, which encode the nicotinic acetylcholine receptor (nAChR) subunits were analysed in 
a sample of 1,050 nicotine-dependent cases. A significant association was found in three gene 
clusters: two distinct loci in the CHRNA5-CHRNA3-CHRNB4, one locus in the CHRNB3-
CHRNA6 and a novel locus in the CHRND-CHRNG. The two distinct loci in CHNA5-
CHRNA3-CHRNB4 are represented by the non-synonymous SNP rs#16969968 
(c.1192G>A) in CHRNA5 and by rs#578776 (c*546C>T) in CHRNA3. [56] 
Besides the dopaminergic system, nicotinic acetylcholine receptors have been implicated in 
nicotine reward and dependency. Two non-synonymous SNPs on exon 5 
(rs#1044396/c.1629G>T and rs#1044397/c.1659G>A) of the CHRNA4 gene, encoding for 
the α4 subunit of the nicotinic acetylcholine receptor, were associated with a lower risk of 
nicotine dependence in Chinese men, which was recently replicated in a European 
population. A G>A variant, rs#2236196, in the 3’-untranslated region of CHRNA4, was 
associated with increased subjective effects of nicotine and higher risk of nicotine addiction. 
[25] 
Several other genetic variations, in genes coding for nicotinic acetylcholine receptor 
subunits, may also be associated with nicotine dependency. Specifically, variation in the 
CHRNA5-CHRNA3-CHRNB4 gene cluster on the long arm of chromosome 15 was 
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associated with a higher risk for lung cancer, smoking a higher number of cigarettes, and 
nicotine dependency. Although some studies suggest that this locus is not associated with 
smoking behaviors, recent evidence proposes that multiple SNPs in this gene cluster are 
associated with a higher number of cigarettes per day and greater nicotine dependency. 
Specifically, the non-synonymous SNP rs#16969968 in CHRNA5 appears to be the most 
promising variant for biological contribution to nicotine dependence, since it has been 
associated repeatedly with higher nicotine addiction, and individuals with the variant allele 
(c.1192G>A) in this SNP had a higher smoking intensity. This SNP causes a change in amino 
acid 398 from asparagines (encoded by the G allele) to aspartic acid (encoded by A, the risk 
allele) which results in the change of an amino acid in the α5-nicotinic receptor protein and 
the insert of this of this single amino acid in in vitro models showed a change in receptor 
function. [25, 55, 58] 
Both rs#16969968 and rs#578776 contribute to the risk of developing nicotine dependence 
equally in men and women. The A-allele of rs#16969968 (c.1192G>A) increases the risk of 
becoming nicotine dependent, compared to non-dependent by 30%; while the A-allele of 
rs#578776 (c.*546C>T) decreases the risk of developing nicotine dependence by more than 
30%. However, different implications of the risk accountable from these genetic variants 
contribute may occur, because of the variation in allele frequencies among ethnic 
populations. [55] 
The findings regarding the chromosome 15 region have revealed different allele frequencies 
according to ethnicity. [55] 
The SNP rs#16969968 is common in the European population (minor allele frequency – 
MAF= 0.42), but it is rare in Asians (MAF=0.01-0.03) and it is absent in Sub Saharan African 
populations (MAF=0). [55] 
The second association, related to rs#578776, has also different allele frequencies in 
different populations. The highest frequencies were identified in Asians (MAF=0.80) and in 
Sub-Saharan population (MAF=0.65), while the lowest was in the Europeans (MAF=0.24). 
Considering that the T allele has been associated to a protective effect against nicotine 
dependence, it may have a superior influence on the African-American and Asian 
populations. [55] 
Genes that alter the pharmacokinetics of nicotine metabolism are also involved in smoking 
phenotypes. In the first phase metabolism, 80% of nicotine is metabolized to the bioactive 
metabolite cotinine, mainly by cytochrome P450 2A6 (CYP2A6) and variability in rate of 
metabolism contributes to vulnerability to tobacco dependence and response to smoking 
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cessation treatment. Cotinine is then metabolized to 3’-hydroxycotinine (3HC) exclusively 
by CYP2A6, so the ratio of conversion of cotinine to 3HC may be used as a phenotypic 
marker for CYP2A6 activity. [25, 59, 60] 
Nicotine and cotinine are also metabolized by glucoronidation via UGT 1A4, 1A9 and 2B10. 
Although glucoronidation is usually a minor pathway of nicotine metabolism, in subjects with 
low CYP2A6 activity, it may be a major determinant of nicotine clearance. [59] 
The CYP2A6 is genetically polymorphic, with over 37 alleles identified for this gene, and this 
variation influences the metabolism of nicotine. Genetic slow metabolizers have longer 
nicotine half-live, resulting in prolonged nicotine plasma levels. They also have reduced 
withdrawal symptoms and higher quitting rates. Genetic variations in CYP2B6, another 
member of the cytochrome P450 family, can also alter smoking behaviors. Individuals with 
one or more copies of CYP2B6*5 allele (c.1459C>T) were shown to have greater craving 
and a higher relapse rate. [25, 59] 
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6. Pharmacogenetics and Drug Addiction Treatment 
 
6.1 Alcohol addiction treatments and Pharmacogenetics 
 
There are currently three FDA-approved medications for the treatment of alcohol 
dependence: naltrexone (both oral and depot), acamprosate and disulfiram. A fourth drug, 
topiramate, has shown compelling evidence of efficacy in two randomized controlled trials 
and frequently is used “off-label” for alcohol dependence. [32] 
In Portugal, there are four approved medications for alcohol dependence, namely 
acamprosate, disulfiram, naltrexone and the newest nalmefene (Selincro®). [61] 
Disulfiram, rarely prescribed since it has potentially serious side effects, has been used as a 
drinking deterrent because, by blocking acetaldehyde metabolism in the alcohol metabolic 
pathway, it produces the very unpleasant flushing syndrome. Naltrexone, a μ-opioid 
receptor antagonist, has been shown to have a modest effect on drinking outcomes. 
Acamprosate, a weak NMDA antagonist, helps maintaining abstinence to alcohol through a 
mechanism that may involve an interaction with glutamate and GABA neurotransmitter 
central systems. Nalmefene is an opioid system modulator, with antagonist activity at the μ 
and δ receptors and partial agonist activity at the k receptor. [62, 63] 
Many patients do not respond to these medications, and side effects often limit usefulness. 
Efforts to try to predict treatment response and side-effect risk of specific medications for 
alcohol dependence treatment with pharmacogenetic analyses have begun. The opioid 
receptor antagonist naltrexone is the medication most studied in pharmacogenetic analyses 
of alcohol treatment trial data. [64] 
OPRM1 is a key candidate gene, since β- endorphin and the μ-opioid receptor have been 
shown to play an important role in the rewarding or reinforcing effects of alcohol. A 
polymorphism in the μ-opioid receptor gene OPRM1, c.118A>G (p.Asn40Asp; rs#1799971) 
produces a threefold increase in β-endorphin binding affinity and potency. Therefore, this is 
the best studied genetic variant with high relevance to alcoholism treatment. [29] 
Evidence from clinical trials suggests that the presence of the variant 108G allele of 
rs#1799971 may predict better treatment response to opioid receptor antagonists, such as 
naltrexone. [29, 64] 
Gelernter et al. (2014) looked for pharmacogenetic effects of several opioid-receptor gene 
polymorphisms, including rs#1799971, in an analysis of a large subgroup of subjects from the 
Pharmacogenomics of Drug Addiction 2014 
 
45 
 
VA Cooperative Study of naltrexone (vs placebo) for the treatment of alcohol dependence. 
In this subset, naltrexone was significantly better than placebo for preventing relapse to any 
heavy drinking, but no effect of opioid-receptor polymorphism moderated the efficacy of 
naltrexone on relapse rates [64] 
In general, alcoholics show reduced central dopaminergic sensitivity that is also associated 
with poor treatment outcome. However, alcoholics carrying the 108G allele have shown 
significantly higher central dopaminergic receptor sensitivity, after one week of abstinence 
that was not seen before detoxification. These findings are in line with another study 
showing that naltrexone-treated alcoholics carrying 108G allele, had significantly lower 
relapse rates and took longer to go back to heavy drinking, compared to AA homozygotes. 
Likewise, a meta-analysis using a random effects model of six studies, published between 
2002 and 2009, that investigated the association between c.118A>G and response to 
naltrexone in alcoholics determined that carriers of G allele had modestly lower relapse 
rates that AA homozygotes (OR = 2.02, 95% CI = 1.26–3.22), but there was no difference in 
abstinence rates . Three placebo-controlled trials have found that alcohol dependent 
individuals with a 108G allele have better clinical responses to naltrexone, including lower 
relapse rates than those with the A allele. [29, 65]  
In a 12 week, randomized clinical trial of naltrexone to reduce drinking in 158 problem 
drinkers, G allele carriers were at increased risk of drinking more when the desire to drink 
was relatively high, and this was attenuated by naltrexone. However, another study did not 
find an effect of this polymorphism on drinking reduction in non-treatment seeking 
alcoholics. [29] 
One relapse-prevention study tested the hypothesis that naltrexone response would be 
associated with allele variations in genes coding for dopaminergic and opioidergic proteins, 
and that acamprosate response would be associated with glutamatergic and GABAergic 
genetic variations influencing function. Treatment-seeking and treatment-non-seeking Dutch 
alcoholics (n=126) were randomly assigned to either naltrexone 50 mg daily or acamprosate 
1.3–2.0 g daily and were exposed to alcohol craving cues. The efficacy of acamprosate on 
craving reduction was enhanced, depending on the C-allele frequency of the SNP of 
GABRA6 gene, whereas the efficacy of naltrexone was enhanced depending on the 
frequency of the T allele. A1- allele homozygotes of the TaqIA DRD2 polymorphism did 
better with acamprosate; those with the A2 allele did better with naltrexone. Both results 
suggest an important role of genetics influencing reward circuitry for treatment of alcohol 
dependence. [64] 
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Additional investigations focused on the ANKK1 Taq1A (rs#1800497) polymorphism, as well 
as on genes involved in GABAergic glutamatergic and opioidergic neurotransmission. In a 
randomized, double-blind placebo controlled study of 108 Dutch individuals, an A2A2 
genotype at the Taq 1A polymorphism of ANNKK1 gene, was associated with increased 
naloxone efficacy, while an A1A1 genotype was associated with an increased ability of 
acamprosate to blunt cue induced cravings. [65] 
 
 
6.2 Cocaine addiction treatments and Pharmacogenetics 
 
Cocaine dependence is common and has social and economic impact but it has no Food and 
Drug Administration (USA) approved specific pharmacotherapy. [66] 
Although a number of innovative pharmacological approaches, such as antidepressants, 
dopamine agonists and anti-epileptic drugs, have had limited success in reducing cocaine use, 
disulfiram has shown some initial promise in treating cocaine dependence. [66, 67] 
Since cocaine addiction has a strong genetic basis, pharmacotherapy for this relapsing brain 
disease should be based on a molecular genetics approach. [66] 
Applying a molecular genetics approach to disulfiram might involve its inhibitory action on 
the copper-containing glycoprotein enzyme DBH. [66] 
According to twin and family studies, plasma levels of DBH vary between unrelated 
individuals and some of these differences are due to polymorphisms close to the DBH gene. 
A few studies link the -1021C>T variant to differences in circulating DBH levels. Several 
studies indicate that this variant has functional impact, by altering transcription and leading to 
decreased plasma levels of DBH. Individuals that are homozygous for the T allele have the 
lowest levels of plasma DBH activity. [41, 66] 
Having in mind the different DBH activities depending on the genetic variant and the 
possibility that disulfiram might not be an effective treatment for cocaine dependence, 
depending on DBH polymorphisms, a clinical trial was conducted to explore this potential 
matching. [66] 
A study that included 74 cocaine dependent subjects were randomly treated with disulfiram 
250 mg daily or placebo, while stabilized on methadone maintenance at 60mg daily. During 
the 10 weeks of the study, urine samples were obtained and tested for the presence of 
cocaine metabolites. The results showed that patients having two of the alleles associated to 
normal activity of DBH (CC, rs#1611115) had a good response to disulfiram, with cocaine 
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positive urines decreasing from 84% to 56%. On the other hand, those with genotypes 
encoding for lower activity (CT and TT) showed no difference from the placebo. This study 
provides evidences that genotyping DBH could be used to identify a group of individuals for 
which disulfiram treatment might be an effective treatment for cocaine dependence. [66] 
Recent evidence suggests that stimulation of the noradrenergic system contributes to 
reward and reinforcement from the drug in individuals abusing of cocaine. Dopamine 
transporter knockout mice continue to self-administer cocaine, suggesting that blockage of 
DAT alone is not sufficient to account for the reinforcing effects of cocaine suggesting that 
other neurotransmitter systems must contribute and be involved in the process. Moreover, 
norepinephrine transporter knockout mice display a reduced response to acute cocaine 
administration. A functional coupling of the noradrenergic system to the dopaminergic 
system may be mediated through the activation of α1A-adrenoceptors, contributing to 
cocaine-induced increase in synaptic levels of norepinephrine and subsequent increase in 
firing of dopamine neurons in VTA and PFC. Preclinical evidence data allowed demonstration 
that pharmacologic blockade of noradrenergic system attenuates reinstatement of cocaine-
seeking behavior in rats. [34] 
Disulfiram inhibits DBH, leading to decrease of norepinephrine levels, which leads to a 
reduction in stimulation of α1A-adrenoceptors. Based on this assumption and in order to 
identify clinical subpopulations, in which the efficacy of disulfiram may be improved, D. 
Shorter et al. (2013) examined cocaine dependent patients based upon ADRA1A genotype. 
The ADRA1A gene codes for the α1A-adrenoceptors and has a polymorphism, rs#1048101, 
in exon 2, coding for the substitution of an arginine (ARG) for a cytosine (CYS) at codon 
347 of the C-terminus, which may alter the functional activity of this receptor. The aim of 
this study was to evaluate whether cocaine addicted patients, carriers of the T allele (TT/ 
TC), Cys347, would have a different response to disulfiram, compared to patients 
homozygous CC, Arg347. [34] 
The results showed that cocaine consumption decreased from 80% to 59% in disulfiram 
group. Furthermore, when the sample is separated into two genotype groups (CC versus 
TT/ TC), cocaine positive urine rates were different between the treatment groups for 
individuals carrying the T allele, but did not differ for those with CC genotype. This result 
suggest that disulfiram reduced the percentage of cocaine positive urines among individuals 
with the CYS conformation of the ADRA1 receptor, but not in those with the ARG 
substitution, related to SNP rs#1048101. [34] 
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These results, combined with the prior study showing that disulfiram reduced cocaine 
consumption in carriers of ADRA1 allele CYS and with DBH -1021C>T polymorphism CC 
(wild type). [34, 66] 
 
 
6.3 Opioid addiction treatments and Pharmacogenetics 
 
Methadone administration and maintenance is the gold standard therapy for heroin addiction 
and successful treatment relies to a certain extent on individual dose optimization. 
Methadone is a synthetic opioid that is administered as a racemic mixture of (R)- and (S)-
enantiomers, although it is the (R)-methadone that accounts for the opioid receptor 
neurochemical activation. Methadone is rapidly absorbed with peak plasma concentrations 2-
4h after oral administration and is metabolized primarily in the liver. As previously referred, 
the major methadone-metabolyzing enzymes are cytochrome P450 CYP3A4, CYP2D6 and 
CYP2B6. The large inter-individual variation in the pharmacokinetics and response to 
methadone may be explained in part by the functional impact of some of these genetic 
variants. [52] 
Concerning CYP2D6 genotypes, the general population is comprised of extensive, 
intermediate, poor and ultra-rapid metabolizers. Ultra-rapid metabolizers were found to 
have unsuccessful methadone treatment therapy, but it has been reported that they have 
good response to buprenorphine that is not significantly metabolized by CYP2D6 enzyme. 
[52] 
Methadone is a substrate of P-glycoprotein 170 (P-gp). The P-gp is a member of the 
subfamily B of the ATP-binding cassette (ABC) superfamily. It has a significant role in drug 
pharmacokinetics. It is encoded by the high polymorphic ABCB1 gene with variation in allele 
frequencies among different populations. Genetic variability in the ABCB1 gene may 
influence methadone distribution by altering P-gp expression and function. The most studied 
SNP is the synonymous sequence variation c.3435C>T (rs#1045642) that has showed to be 
related to lower in vivo duodenal P-gp expression and also lower mRNA expression in 
human liver samples. Variants c.1236T (rs#1128503, c.1236T>C), c.2677T (rs#2032582, 
c.2677T>A) and c.3435T (rs#1045642, c.3435C>T) were reported to minimize P-gp activity 
in vitro in a substrate-specific manner. [52] 
A study of 179 European individuals shows that carriers of the CYP2B6*6 allele 
(rs#3745274) had an increased risk of prolonged QTc interval when treated with 
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methadone. A second study of 245 individuals undergoing methadone therapy has shown 
that the CYP2B6*6 allele (rs3745274) was associated with higher levels of the drug. 
However there was no effect on the success of treatment. [65] 
Buprenorphine is a synthetic opioid with primarily MOR partial agonism and modest κ-opioid 
receptor activity. It is available for heroin detoxification as a single agent but marketed 
primarily in the United States in a combination preparation with naloxone for maintenance 
therapy. Buprenorphine has a much shorter terminal half-life (3 to 5h) than methadone (24 o 
36h), but dissociates slowly from MOR over 24 to 48h, allowing for daily or even once every 
3-day dosing. Because it is a partial agonist with strong MOR affinity, buprenorphine can 
induce withdrawal symptoms in moderately to highly opiate tolerant individuals. [17] 
The standard medications used in the treatment of opiate dependence, such as methadone 
and buprenorphine, are all primarily metabolized by CYP3A4. Polymorphisms that affect 
CYP3A4 function may influence the efficacy of these treatment agents. [17] 
On the other hand, treating mixed drug abusing consumptions, which are very common, is a 
challenge in addiction therapeutics. [46] 
The three opioid receptors also play important roles in the reinforcing properties of non-
opioid drugs, such as cocaine, and alcohol. Cocaine is thought to act primarily at the 
dopamine transporter and the dopamine system is intimately interconnected with the 
endogenous opioid systems. Repeated administration of cocaine evokes a down-regulation of 
δ-receptor density in the NAc. It was found that a single cocaine exposure enhanced both μ-
receptor and κ-receptor aversion through a circuit involving the ventral tegmental area, in 
which dopamine neurons are abundant. Furthermore μ- and δ-receptor agonists sensitize 
animals to the rewarding effect of cocaine and alcohol, whereas κ-receptor agonists inhibit 
this function. Moreover, pharmacological blockage of the endogenous opioid system by μ-
and δ-receptor antagonists prevent ethanol from activating the dopamine system and 
reduces ethanol craving and consumption. Thus, μ-and δ-receptor antagonists can be useful 
in the treatment of alcohol dependence. Naltrexone is thought to exert its action primarily 
by blocking the μ-receptor and is one of the rare approved pharmacotherapies for alcohol 
and drug addiction. [46] 
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6.4 Nicotine dependence treatments and Pharmacogenetics 
 
Currently, three classes of medications have been approved for smoking cessation: nicotine 
replacement products (patch, gum, spray and inhaler), bupropion and varenicline. [59] 
The main action of nicotine replacement medication aims to replace partially the nicotine 
from cigarettes to produce the relief of withdrawal symptoms when a person stops tobacco 
consumption and to reduce craving. Amelioration of these symptoms is observed with 
relatively low blood levels of nicotine. [59, 68] 
The mechanism of action of bupropion as a support in smoking cessation is unknown. It is 
presumed that its effect is mediated by a noradrenergic and/or dopaminergic mechanism, 
since bupropion increases brain levels of dopamine and norepinephrine, simulating the 
effects of nicotine on these neurotransmitters. Bupropion also has some nicotine receptor-
blocking activity. [59, 69] 
Varenicline was synthesized with the goal of developing a specific antagonist for the α4β2 
nAchR. Varenicline is a partial agonist of α4β2 receptor in vivo and produces less of a 
response than nicotine (~50%) but, at the same time, it blocks the effects of any nicotine 
added to the system. Clinical trials have showed that varenicline is superior to bupropion 
when evaluating smoking abstinence rates. [59, 69] 
A number of pharmacogenetic studies have been carried, focusing primarily on candidate 
genes related to nicotine reward and nicotine metabolism pathways. [59] 
The gene DRD2 has been investigated and it was found that women with the DRD2-ANKK1 
Taq1 A1 variant presented a considerable benefit from nicotine patches. In a double-blind 
randomized clinical trial with 368 current smokers, two other DRD2 polymorphisms 
(c.957C>T - rs#6277 and -141C Ins/ Del rs#1799732) have been demonstrated to influence 
treatment response to nicotine replacement therapy. Smokers carrying the allele -141Cdel 
had higher smoking quit rates on nicotine replacement therapies compared to homozygous 
for the -141Cins allele. The same study also demonstrated that for the c.957C>T variation, 
smokers with the C-allele were less likely to be abstinent at the end of treatment than 
smokers with TT genotype. [68, 70] 
Novel CYP2A6 genetic variants have been discovered, but only some of these variants 
demonstrated to modify enzyme activity. While the CYP2A6*2 allele and CYP2A6*4 are fully 
inactive, others including CYP2A6*9 and CYP2A6*12 result in decreased enzyme activity. 
Slow metabolizers are those individuals carrying at least one copy of the inactive variants 
(CYP2A6*2 and CYP2A6*4) or having two CYP2A6*9A or CYP2A6*12A alleles. [68] 
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Smokers that are slow metabolizers with the CYP2A6*4 allele showed higher relapse rates 
following nicotine patch, compared with smokers with CYP2A6*1. [68] 
The DRD2 polymorphism -141CIns/Del has also been analyzed for bupropion treatment. 
Smokers who were homozygous for the -141CIns allele showed higher abstinence rates with 
bupropion than smokers with the -141CDel allele. Comparing the data regarding this 
polymorphism with nicotine replacement therapy, these results suggested that smokers with 
InsC/InsC genotype may respond better to bupropion, while individuals that are 
homozygous DelC/ DelC may have a better response to nicotine replacement therapy. [68, 
70] 
O’Gara and colleagues (2007) conducted a study of the influence of SLC6A3polymorphisms, 
related to dopamine transporter DAT1, to the outcome of smoking cessation treatment 
with bupropion or nicotine replacement therapy. Smokers carrying the 9-repeat allele at 3’ 
UTR VNTR, or the 2-repeat allele at VNTR in intron 8 were more likely to quit smoking 
after treatment. However, these results were only observable one week after smoking 
cessation. [68, 71] 
Bupropion is metabolized to a primary metabolite, hydroxybupropion, by CYP2B6. Some 
polymorphisms of CYP2B6 gene have been shown to have no influence on bupropion 
pharmacokinetics. For example, smokers homozygous CC for CYP2B6*5 (c.1459C>T) were 
more likely to be abstinent from smoking with bupropion treatment, than those carrying the 
T-allele (slow metabolizers). In the same study, T-allele was reported to be associated with 
higher relapse rates and greater increases in cravings [68] 
The CHRNA5-CNHRNA3-CHRNB4 cluster variants have been less consistently associated 
with cessation outcomes than with smoking heaviness measures. However, some studies 
have shown association between the CHRNA5-CNHRNA3-CHRNB4 region and successful 
in smoking cessation. It was also found that the same genetic risk variants that contribute to 
smoking heaviness and nicotine dependence also predicted smoking cessation [72]. 
The Pharmacogenetics of Nicotine Addiction Treatment (PNAT) Consortium was formed in 
2005, aiming to identify the role of pharmacokinetic and pharmacodynamic gene variation on 
nicotine dependence and metabolism phenotypes, with focus on smoking cessation and 
medication response. In this context, Bergen et al. (2013) conducted an association analysis 
of the nAChR candidate gene variations with abstinence at end of treatment (EOT) and 6 
month after the quit day in 2,633 treatment-seeking smokers. The results showed that “risk” 
haplotype (rs#588765 - c.106+7258T>C and rs#1051730 - c.645C>T) previously associated 
with smoking heaviness was significantly associated with increased abstinence in the nicotine 
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replacement therapy group, but not with other therapies, such as bupropion or varenicline. 
[73] 
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7. Conclusion and Future Perspectives 
 
Drug addiction is a complex disease which is influenced by environmental and genetic 
factors. It is a neurodegenerative disorder that affects millions of people worldwide and 
causes social impairment and has important associated co-morbidities. Drug addiction 
remains an unsolved health issue and has limited treatment options currently available. 
Furthermore, the existing medications were not developed having a thorough knowledge of 
genetic and neurobiological causes of the disease. Accordingly, these are a few reasons why 
a huge effort has been made to evaluate the genetic causes underlying this disease and to go 
further in the understanding of the susceptibility of certain individuals to substance abuse and 
heterogeneity in therapeutic response. 
A significant attempt to reach a deep knowledge has been made in the past 20 years when 
the twin and adoption studies were carried out to evaluate if heritability could play a role in 
dependences. Since then, science and technique has evolved, allowing a faster development 
in this area. Starting with PET scans that allow having a better and enhanced understanding 
of brain areas involved in reward circuits; also, more refined and effective DNA sequencing 
techniques, which enable the identification of genetic variations involved in drug addiction, 
have been contributing for the significant amount of data produced leading to a more 
detailed understanding of the neurobiologic and genetic etiology of drug addiction. 
Many GWAS for several drug addictions were conducted. A few SNPs achieved statistically 
significance, being considered genome wide-significant and numerous candidate genes have 
been implicated in the etiology and response to treatment. However, in several studies the 
results were unexpectedly conflicting or did not reach statistic significance, which brings 
some confusion to the field and compromises the effective set up of rational clinical tools 
based on genetic and neurobiological data. 
We have reached the point where the undertaking has given some results and the necessary 
techniques are available. 
So, what is next? 
More replication data is needed concerning some genetic variants to allow the identification 
of functional variants, but also the need for larger population samples has become clear for 
detecting small effect variants from the many genes accountable for addiction. 
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It is also important to take a better look at study design, such as the selection of samples, 
that must be carried carefully to prevent population stratification and also a consistent 
phenotype should be chosen. 
In some studies, the results seem to fail because of the control group (never users vs former 
users); thus, this group should be thoroughly selected to avoid bias in the results. 
With the upcoming of NGS genetic analysis, new challenges will rise, such as data storage 
and the need of tools for quality control of such amount of data, leading to the need of 
bioinformatics expertise in the working teams. 
Genetic information has proved to be important not only in what concerns the cause of the 
disease, but also in the response to treatment, with clinical trials showing that genetic 
variants can influence the clinical response to a high extent. More clinical trials concerning 
drug dependence treatment should be conducted to improve the efficacy of clinical 
response, and taking into account genetics and functional phenotypic variations. 
The main goal of pharmacogenomics of addiction, which is the development of medication 
based on the deep knowledge of the genetic underlying the causes of the disease – the truly 
personalized medicine, seems yet to be far, since this development should begin with 
validated functional variants. 
However, efforts are being made in that direction, contributing for improving understanding 
and expecting to improve quality of life of patients. 
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